-
Conjustar Biologics Awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China – 2025"
Conjustar Biologics (星联肽生物), a clinical-stage biotech company focused on miniaturized conjugate drugs—peptide-drug conjugates (PDCs) and Nanobody-drug conjugates (NDCs)—has been awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China (2025)" at the 2026 OneBD Pharmaceutical Investment & BD Conference, held May 21 in Shanghai.
2026-06-08
-
Presentations in European Society for Medical Oncology (ESMO) Congress 2025
SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients with advanced or metastatic solid tumors: Results from dose-escalation study
2025-11-18
-
EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)
2025-06-04
